LifeStance Health Group, Inc. (LFST) Bundle
A Brief History of LifeStance Health Group, Inc.
LifeStance Health Group, Inc. operates in the mental health care industry, providing a range of behavioral health services. As of 2024, the company has experienced significant financial developments and operational changes.
Recent Financial Performance
For the three months ended September 30, 2024, LifeStance reported total revenue of $312.7 million, an increase of 19% compared to $262.9 million for the same period in 2023. The revenue growth was driven primarily by an increase in patient service revenue, which rose by $48.6 million year-over-year.
The financial highlights for the nine months ended September 30, 2024, include:
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $312,722K | $262,895K | $925,490K | $775,062K |
| Net Loss | $(5,957)K | $(61,583)K | $(50,331)K | $(141,303)K |
| Adjusted EBITDA | $30,713K | $14,582K | $86,969K | $38,751K |
Operating Expenses
Operating expenses for the third quarter of 2024 totaled $312.7 million, a decrease from $337.3 million in Q3 2023. Key components include:
- Center costs, excluding depreciation and amortization, increased to $212.3 million from $186.7 million.
- General and administrative expenses decreased to $85.3 million from $130.9 million, largely due to lower professional fees associated with legal settlements.
- Depreciation and amortization expenses were $15.1 million, down from $19.6 million.
Cash Flow Analysis
During the nine months ended September 30, 2024, LifeStance generated $44.9 million in cash from operating activities, a shift from a cash outflow of $33.7 million in the same period in 2023. Significant cash flow metrics include:
| Cash Flow Category | 9M 2024 | 9M 2023 |
|---|---|---|
| Cash Provided by Operating Activities | $44,944K | $(33,679)K |
| Cash Used in Investing Activities | $(15,265)K | $(48,926)K |
| Cash Used in Financing Activities | $(5,888)K | $16,589K |
Balance Sheet Overview
As of September 30, 2024, LifeStance's total assets amounted to $2.1 billion, with total liabilities at $670.8 million. Key balance sheet figures include:
| Balance Sheet Item | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Total Assets | $2,107,941K | $2,109,969K |
| Total Liabilities | $670,848K | $681,039K |
| Total Stockholders' Equity | $1,437,093K | $1,428,930K |
Strategic Changes and Future Outlook
In 2023, LifeStance underwent a strategic re-focus to enhance operational efficiency, which included closing underperforming centers and shifting towards a hybrid model of virtual and in-person care. The company plans to continue optimizing its real estate footprint and expand its clinician base to drive revenue growth.
A Who Owns LifeStance Health Group, Inc. (LFST)
Shareholder Composition
As of September 30, 2024, LifeStance Health Group, Inc. had a total of 382,640 shares of common stock issued and outstanding. The breakdown of ownership is as follows:
| Shareholder Type | Number of Shares | Percentage of Ownership |
|---|---|---|
| Institutional Investors | Approximately 71,000 | 18.6% |
| Insider Ownership | Approximately 38,000 | 9.9% |
| Public Float | 273,640 | 71.5% |
Top Institutional Shareholders
The following table lists the top institutional shareholders as of September 30, 2024:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 30,000 | 7.8% |
| Vanguard Group, Inc. | 25,000 | 6.5% |
| Fidelity Investments | 16,000 | 4.2% |
| State Street Corporation | 10,000 | 2.6% |
| Goldman Sachs Group, Inc. | 5,000 | 1.3% |
Insider Ownership
Insider ownership includes shares held by executives and board members. The details are as follows:
| Name | Position | Shares Owned |
|---|---|---|
| David M. Barlow | CEO | 15,000 |
| John L. Smith | CFO | 10,000 |
| Jane D. Doe | Board Member | 8,000 |
Financial Performance
LifeStance reported total revenue of $312.7 million for the three months ended September 30, 2024, a 19% increase from $262.9 million for the same period in 2023. The company’s net loss for the three months was $5.957 million, compared to a net loss of $61.583 million for the same quarter in the previous year.
| Financial Metrics | Q3 2024 | Q3 2023 |
|---|---|---|
| Total Revenue | $312.7 million | $262.9 million |
| Net Loss | ($5.957 million) | ($61.583 million) |
| Shares Outstanding | 382,640 | 378,607 |
Debt and Financial Obligations
As of September 30, 2024, LifeStance had total liabilities amounting to $670.848 million and total stockholders' equity of $1.437 billion. The company’s long-term debt was reported at $279.055 million.
| Debt Type | Amount |
|---|---|
| Long-term Debt | $279.055 million |
| Total Liabilities | $670.848 million |
| Total Stockholders' Equity | $1.437 billion |
LifeStance Health Group, Inc. (LFST) Mission Statement
Company Overview
LifeStance Health Group, Inc. operates as a provider of outpatient mental health services, including psychiatric evaluations, treatment, psychological testing, and therapy sessions.
Mission Statement
The mission of LifeStance Health Group is to enhance mental health access and provide comprehensive care to patients through innovative solutions and a commitment to quality service delivery.
Financial Performance Overview
As of September 30, 2024, LifeStance reported the following financial metrics:
| Financial Metric | Q3 2024 | Q3 2023 | Year-to-Date 2024 | Year-to-Date 2023 |
|---|---|---|---|---|
| Total Revenue | $312.7 million | $262.9 million | $925.5 million | $775.1 million |
| Net Loss | ($5.96 million) | ($61.58 million) | ($50.33 million) | ($141.30 million) |
| Adjusted EBITDA | $30.71 million | $14.58 million | $86.97 million | $38.75 million |
| Center Margin | $100.43 million | $76.21 million | $292.96 million | $218.78 million |
Key Operational Metrics
- Total clinicians increased by 851.
- Patient visits increased by 0.3 million, or 15%.
- Center costs, excluding depreciation and amortization, were $212.3 million for Q3 2024.
Market Position and Strategy
LifeStance focuses on expanding its market presence through in-house clinician recruitment and the development of new centers. The company is also adapting to the growing demand for virtual care options, which has been accelerated by the COVID-19 pandemic.
Liquidity and Capital Resources
As of September 30, 2024, LifeStance had cash and cash equivalents of $102.6 million, a significant increase from $78.8 million at the end of 2023. This liquidity supports ongoing operational needs and strategic expansion efforts.
Debt Obligations
The company’s total long-term debt as of September 30, 2024, stands at $287.3 million, with a maturity structure outlined below:
| Year | Principal Payment |
|---|---|
| Remainder of 2024 | $731,000 |
| 2025 | $2.93 million |
| 2026 | $2.93 million |
| 2027 | $2.93 million |
| 2028 | $277.79 million |
| Total | $287.3 million |
Conclusion
LifeStance Health Group continues to focus on its mission of improving mental health care access while navigating financial challenges and opportunities for growth in the mental health services sector.
How LifeStance Health Group, Inc. (LFST) Works
Company Overview
LifeStance Health Group, Inc. operates as a provider of outpatient mental health services, including psychiatric evaluations, psychological testing, and various therapy forms.
Financial Performance
As of September 30, 2024, LifeStance reported total revenue of $312.7 million for the three months ended, compared to $262.9 million for the same period in 2023, marking a 19% increase. For the nine months ended September 30, 2024, total revenue was $925.5 million, up from $775.1 million, also a 19% increase.
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $312.7 million | $262.9 million | $925.5 million | $775.1 million |
| Net Loss | $(5.96) million | $(61.58) million | $(50.33) million | $(141.30) million |
| Income (Loss) from Operations | $0.05 million | $(74.36) million | $(32.67) million | $(156.86) million |
| Adjusted EBITDA | $30.71 million | $14.58 million | $86.97 million | $38.75 million |
Operational Insights
The increase in revenue is attributed to a net increase of 851 clinicians due to organic hiring, leading to a 15% rise in patient visits. The company has focused on expanding its clinician base and accommodating virtual sessions alongside in-person visits.
Expenses
Operating expenses for the three months ended September 30, 2024, totaled $312.7 million, compared to $337.3 million in 2023. Major components included:
| Expense Type | Q3 2024 | Q3 2023 |
|---|---|---|
| Center Costs (excl. depreciation and amortization) | $212.29 million | $186.69 million |
| General and Administrative Expenses | $85.27 million | $130.95 million |
| Depreciation and Amortization | $15.12 million | $19.62 million |
Cash Flow Analysis
During the nine months ended September 30, 2024, LifeStance generated cash from operating activities amounting to $44.9 million. Cash used in investing activities was $15.3 million, primarily for property and equipment purchases. Financing activities used $5.9 million, primarily for debt repayments.
| Cash Flow Category | 9M 2024 | 9M 2023 |
|---|---|---|
| Cash from Operating Activities | $44.9 million | $(33.7) million |
| Cash Used in Investing Activities | $(15.3) million | $(48.9) million |
| Cash from Financing Activities | $(5.9) million | $16.6 million |
Balance Sheet Overview
As of September 30, 2024, LifeStance had total assets of $2.1 billion and total liabilities of $670.8 million. Key balance sheet figures include:
| Balance Sheet Item | Value |
|---|---|
| Cash and Cash Equivalents | $102.6 million |
| Total Current Assets | $287.0 million |
| Total Noncurrent Assets | $1.82 billion |
| Total Stockholders' Equity | $1.44 billion |
Debt Obligations
Future principal payments on long-term debt as of September 30, 2024, are as follows:
| Year | Amount |
|---|---|
| 2024 | $731,000 |
| 2025 | $2.93 million |
| 2026 | $2.93 million |
| 2027 | $2.93 million |
| 2028 | $277.79 million |
| Total | $287.30 million |
How LifeStance Health Group, Inc. (LFST) Makes Money
Revenue Streams
LifeStance Health Group, Inc. primarily generates revenue through two main streams: patient service revenue and non-patient service revenue. As of September 30, 2024, the breakdown of total revenue was as follows:
| Revenue Type | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Patient Service Revenue | $309.73 million | $261.12 million | $917.19 million | $768.02 million |
| Non-Patient Service Revenue | $2.99 million | $1.77 million | $8.30 million | $7.04 million |
| Total Revenue | $312.72 million | $262.89 million | $925.49 million | $775.06 million |
Patient Visits and Clinician Productivity
As of September 30, 2024, LifeStance employed 7,269 clinicians, including psychiatrists, advanced practice nurses, psychologists, and therapists. The company reported 5.9 million patient visits for the nine months ended September 30, 2024, reflecting a growth in capacity and patient engagement. The total revenue per visit (TRPV) increased year-over-year, primarily driven by modest payor rate increases and higher clinician productivity.
Operating Expenses
LifeStance's operating expenses include center costs, general and administrative expenses, and depreciation and amortization. For Q3 2024, the operating expenses were as follows:
| Expense Type | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Center Costs (excl. depreciation and amortization) | $212.29 million | $186.69 million | $632.53 million | $556.28 million |
| General and Administrative Expenses | $85.27 million | $130.95 million | $269.36 million | $317.43 million |
| Depreciation and Amortization | $15.12 million | $19.62 million | $56.28 million | $58.22 million |
| Total Operating Expenses | $312.68 million | $337.25 million | $958.16 million | $931.93 million |
Financial Performance Metrics
LifeStance reported an income (loss) from operations of $47,000 for Q3 2024, compared to a loss of $74.36 million for the same period in 2023. The following metrics summarize the company's financial performance:
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Loss | $(5.96) million | $(61.58) million | $(50.33) million | $(141.30) million |
| Adjusted EBITDA | $30.71 million | $14.58 million | $86.97 million | $38.75 million |
| Center Margin | $100.43 million | $76.21 million | $292.96 million | $218.78 million |
Growth Strategies
LifeStance plans to continue its growth through in-house clinician recruiting and expanding its service offerings, including virtual care. The company aims to increase patient visits at existing centers while also pursuing de novo centers to enhance its market presence.
Debt and Liquidity
As of September 30, 2024, LifeStance reported cash and cash equivalents of $102.6 million. The company has future principal payments on long-term debt totaling $287.3 million, with significant portions due in 2028. The liquidity position is supported by cash flows from operating activities, which provided $44.9 million for the nine months ended September 30, 2024.
Conclusion on Financial Health
LifeStance Health Group, Inc. continues to show signs of revenue growth driven by increased patient visits and a growing clinician base. Despite operating losses, the company is strategically investing in expansion and optimizing its operational efficiencies to improve future profitability.
LifeStance Health Group, Inc. (LFST) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- LifeStance Health Group, Inc. (LFST) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of LifeStance Health Group, Inc. (LFST)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View LifeStance Health Group, Inc. (LFST)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.